Issue 3/2012

  • Are released GM mosquitos safe?

    In this issue:

    • Novartis poised to enter HCV market with Enanta compound
    • Norway to use sequencing data in the country’s healthcare system
    • Oxford Nanopore shakes up Next-Gen sequencing market
    • BIO-Europe Spring: Antibodies – Unlocking new markets
    • Spain leads EU project for iPSCs in cell replacement therapies
    • Bioton joins forces with Actavis to develop biosimilar insulins
    • European Commission presents 2020 roadmap to bioeconomy

Volume 2015

Volume 2014

Volume 2013

Volume 2012

© 2007-2015 BIOCOM

http://www.european-biotechnology-news.com/magazine/ebsin/2012/3/pos/1.html?sort=desc&cHash=8305edff5982cb307c5ea48106acb36a

Kurszettel

Alle Kurse

TOP

  • BAVARIAN NORDIC (D)44.62 EUR12.34%
  • MOLOGEN (D)5.20 EUR7.00%
  • BRITISH TECHNOLOGY GROUP (UK)686.00 GBP6.94%

FLOP

  • CYTOS (CH)0.50 CHF-9.09%
  • NOVACYT (F)4.99 EUR-6.90%
  • EPIGENOMICS (D)5.12 EUR-5.19%

TOP

  • DBV Technologies (F)54.26 EUR20.3%
  • Allergy Therapeutics (UK)23.50 GBP15.3%
  • BIOINVENT INTERNATIONAL AB (S)2.58 SEK13.7%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-50.0%
  • TRANSGENE (F)3.80 EUR-26.5%
  • NORDIC NANOVECTOR (N)25.50 NOK-25.7%

TOP

  • 4SC (D)4.90 EUR375.7%
  • ADOCIA (F)66.29 EUR341.9%
  • VERONA PHARMA (UK)5.10 GBP314.6%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-87.5%
  • ACTIVE BIOTECH (S)9.00 SEK-70.1%
  • NEOVACS (F)1.14 EUR-68.2%

No liability assumed, Date: 03.07.2015